Kostinov, М.P.; Chuchalin, A.; Chebykina, A.; Akhmatova, N.K.; Polishchuk, V.B.; Kryukova, N.; Kostinova, A.M.; Vlasenko, A.E.; Cherdantsev, A.P.; Solovieva, I.L.; Loktionova, M.; Shmitko, A.D.; Gladkova, L.S.; Albahansa Mana, Y. Vaccination against Influenza: Clinical and Cytokine Profile of Patients with Asthma and Chronic Obstructive Pulmonary Disease. Preprints2023, 2023092135. https://doi.org/10.20944/preprints202309.2135.v1
APA Style
Kostinov, М.P., Chuchalin, A., Chebykina, A., Akhmatova, N.K., Polishchuk, V.B., Kryukova, N., Kostinova, A.M., Vlasenko, A.E., Cherdantsev, A.P., Solovieva, I.L., Loktionova, M., Shmitko, A.D., Gladkova, L.S., & Albahansa Mana, Y. (2023). Vaccination against Influenza: Clinical and Cytokine Profile of Patients with Asthma and Chronic Obstructive Pulmonary Disease. Preprints. https://doi.org/10.20944/preprints202309.2135.v1
Chicago/Turabian Style
Kostinov, М.P., Lilya Solomonovna Gladkova and Yvette Albahansa Mana. 2023 "Vaccination against Influenza: Clinical and Cytokine Profile of Patients with Asthma and Chronic Obstructive Pulmonary Disease" Preprints. https://doi.org/10.20944/preprints202309.2135.v1
Abstract
Background: Influenza vaccine is a tool for preventing infection and reducing exacerbations in patients with asthma and chronic obstructive pulmonary disease (COPD). Purpose of this study is to investigate dynamics of CRP and serum cytokines (IL-2, IL-6, IL-10, IL-17) in patients with asthma and COPD, as well as to perform a correlation analysis with the clinical parameters of the disease manifestation. Methods: The study included 34 patients with asthma, 20 patients with COPD vaccinated against influenza during a period of remission from 2 to 4 weeks, both groups being under a basic maintenance therapy, and 26 healthy individuals vaccinated with the trivalent polymer-subunit vaccine Grippol® Plus, containing 5 µg of influenza virus strains and 500 µg of azoximer bromide. Results: Observing patients with asthma and COPD, during a year after the vaccination, has revealed a significant reduction in exacerbations frequency (p < 0.05) and duration (p < 0.05) of the bronchial obstructive syndrome (BF). Before the vaccination the IL-6 level in patients with asthma had a direct moderate correlation with duration of exacerbations of the underlying disease (p < 0.05), along with the number of systemic corticosteroids courses during exacerbations (p < 0.05). In 12 months after the vaccination, while assessing cytokine profile of all study groups, a significant reduction in the level of IL-6 was observed, compared to the baseline values (p< 0.05). Conclusion: Conducted analysis of immunological, clinical, and functional parameters of patients with asthma and COPD has proven for influenza vaccine to be effective in BF patients.
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
,
,
,
,
